Objective To analyze one case of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by durvalumab, in order to call clinical attention to new immune-related adverse events (irAEs).Methods One case of RCCEP occurred in a patient with advanced lung cancer during the use of durvalumab was analyzed, and the possible causes of RCCEP induced by durvalumab were described by combining the literature review.Results This case of RCCEP was likely induced by durvalumab. After treated with apatinib, the symptoms of RCCEP were relieved.Conclusion The clinical use of durvalumab should be monitored more vigorously, and drug use education should be strengthened. It is also necessary to observe the skin condition of patients regularly, to obtain timely and accurately the relevant symptoms of patients, and to give targeted treatment plans, so that can effectively avoid the aggravation of the adverse reaction symptoms of patients.